Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of parsaclisib administered orally to participants with autoimmune hemolytic anemia (AIHA) who have decreased hemoglobin and evidence of ongoing hemolysis that requires treatment intervention.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03538041
Study type Interventional
Source Incyte Corporation
Contact
Status Completed
Phase Phase 2
Start date November 21, 2018
Completion date April 2, 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05057481 - Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus Phase 3
Recruiting NCT05937828 - OBS'CEREVANCE: French Cohort of Pediatric Autoimmune Cytopenia
Recruiting NCT05263817 - A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis Early Phase 1
Completed NCT03269292 - Clinical Characteristics and Treatment Outcomes of Patients With Autoimmune Hemolytic Anemia
Recruiting NCT05694312 - Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL Phase 2
Recruiting NCT03918265 - Tacrolimus Treatment for Refractory Autoimmune Cytopenia Phase 4
Completed NCT02389231 - Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment Phase 1/Phase 2
Active, not recruiting NCT03576742 - Severe Immune Cytopenia Registry Www.Sic-reg.Org
Active, not recruiting NCT04657094 - Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia Phase 2
Recruiting NCT02828670 - Role of T Follicular Helper Cells in Autoimmune Hemolytic Anemia (TFH in AIHA)
Recruiting NCT02877706 - French Registry of Adult Patients With Immune Thrombocytopenia and Autoimmune Hemolytic Anemia
Recruiting NCT05931718 - Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia
Completed NCT02158195 - Immunopathology of Autoimmune Hemolytic Anemia
Completed NCT00001630 - Treatment of Autoimmune Thrombocytopenia (AITP) Phase 1
Withdrawn NCT04039477 - A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP Phase 2
Recruiting NCT04024202 - Data Registry of Auto Immune Hemolytic Anemia
Not yet recruiting NCT05711264 - Presence of Circulating Cluster of Differentiation 4 Positive 28 Null T Helper Lymphocytes(CD4+CD28-) in Patients With Autoimmune Hemolytic Anemia.
Completed NCT02689986 - Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease Phase 2
Recruiting NCT06212154 - CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy Phase 1
Completed NCT04057703 - Balance Benefit / Risk of Immunomodulatory Treatments at the Child and Adolescent for Autoimmune Cytopenia.